Get the latest news, insights, and market updates on AXSM (Axsome Therapeutics, Inc.). Explore the news page 7 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy
Axsome obtains exclusive global rights to AZD7325, a novel oral selective GABAA α2,3 receptor positive allosteric modulator Deepens Axsome’s broad and innovative neuroscience portfolio with a synergistic early-stage program for epilepsy NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has entered into an agreement to obtain exclusi Nov 6, 2025 - $AXSM
Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics
Baergic shareholders eligible to receive up to approximately $82 million in potential development, regulatory, and sales milestones plus a tiered mid-to-high single digit royalty on global net sales from AxsomeMIAMI, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (OTC: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, and its majority-owned subsidiary, Baergic Nov 6, 2025 - $AXSM
Is Axsome Therapeutics Set for More Gains After 54% Rally and Clinical Pipeline News?
Curious whether Axsome Therapeutics is truly a hidden gem or just riding biotech buzz? You are not alone; plenty of investors are wondering if the current price really offers value. The stock has delivered a massive 54.7% return over the past year and is already up over 54% year to date, so the market’s curiosity is clearly piqued. Recent news headlines have highlighted Axsome’s late-stage clinical pipeline and progress with new drug approvals, which seem to be fueling... Nov 4, 2025 - $AXSM
Axsome Therapeutics (AXSM): Net Margin Stays Negative as Growth Expectations Drive Up Valuation Debate
Axsome Therapeutics (AXSM) remains in the red, with losses climbing at an average rate of 24.5% annually over the past five years. Despite ongoing negative earnings, analysts are optimistic, projecting earnings to grow 67.15% per year and revenue to rise 33.3% per year. These rates substantially outpace the broader US market’s 10.5% average. Although the company’s net profit margin has not improved and its Price-To-Sales Ratio of 13.6x is well above industry benchmarks, expectations of... Nov 4, 2025 - $AXSM
Axsome Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Total 3Q 2025 net product revenue of $171.0 million, representing 63% year-over-year growth AUVELITY® 3Q 2025 net product sales of $136.1 million, representing 69% year-over-year growth SUNOSI® 3Q 2025 net product revenue of $32.8 million, representing 35% year-over-year growth SYMBRAVO® 3Q 2025 net product sales of $2.1 million sNDA for AXS-05 in Alzheimer’s disease agitation submitted to the FDA Company to host conference call today at 8:00 AM Eastern NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) - Nov 3, 2025 - $AXSM
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple